Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Long-term testosterone undecanoate treatment in the elderly testosterone deficient male - an observational cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Anogenital distance, male factor infertility and time to pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. European Academy of Andrology (EAA): Annual Report 2021

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. ANDRONET: A new European network to boost research coordination, education and public awareness in andrology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Quarterly intramuscular injections with long-acting testosterone undecanoate (TU) provide stable serum testosterone concentrations over time and are therefore preferred by many testosterone-deficient patients. However, the use of long-acting TU in elderly patients is limited due to lack of safety and feasibility studies.

OBJECTIVE: To investigate long-acting TU pharmacokinetics and assess differences in treatment regimens and risk of adverse outcomes in younger versus elderly testosterone-deficient patients.

MATERIALS AND METHODS: Single-center longitudinal observational study. Patients who initiated long-acting TU treatment between 2005 and 2010 were included. Elderly patients were born before 1956 and younger patients between 1965 and 1985. TU dose was adjusted yearly through shortening or prolongation of time between injections. Treatment targets were as follows: (1) free testosterone between 0 and -1 SD from the age-adjusted mean, (2) no symptoms of testosterone deficiency, and (3) hematocrit within the normal range.

RESULTS: The study population consisted of 63 elderly and 63 younger patients. Median follow-up time during testosterone replacement was 12.1 years. Increasing intervals between TU injections were performed 44% more often in the elderly compared to younger patients and time between TU injections were prolonged 4% more in the elderly patients. The hematocrit, as well as the hematocrit for a given serum testosterone (hematocrit: testosterone ratio), increased with treatment time but did not differ between age groups. During follow-up, 40% of patients-both elderly and younger-experienced polycythemia. Risk of polycythemia did not differ with age.

DISCUSSION AND CONCLUSION: An increased number of adjustments of TU dose are necessary in elderly patients in order to reach treatment targets. TU treatment in elderly testosterone-deficient patients is not associated with an increased risk of polycythemia compared to younger patients if age-adjusted treatment targets are reached.

Udgave nummer2
Sider (fra-til)322-332
Antal sider11
StatusUdgivet - feb. 2022

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 68856973